Celularity

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced publication of a study in Frontiers in Immunology describing the antiviral role of its placental-derived natural killer (NK) cells (CYNK) in IAV infections.

Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

Camping World Hlds

FTC Solar

Dave & Buster's

Smith & Wesson Brands

Wheels Up Experience

Axcelis Technologies

September is living up to its reputation for being one of the worst months to own stocks.

7 Small-Cap Stocks to Buy Now for Extraordinary Gains

Advent Technologies Holdings

Amyris

Avaya Holdings

Coeur Mining

What To Watch With 5 Hot Penny Stocks This Week The post Wall Street Stock Market Today: Penny Stocks To Watch Before Fed Meeting appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Wall Street Stock Market Today: Penny Stocks To Watch Before Fed Meeting

FLORHAM PARK, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that it entered into a Pre-Paid Advance Agreement (the “Agreement”) with YA II PN, LTD (“Yorkville”), an affiliate of Yorkville Advisors Global, LP.

Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville

Andersons

LifeVantage

Clearway Energy

Investors may want to consider the following non-cyclical stocks as their earnings yields (as calculated by Joel Greenblatt (Trades, Portfolio)'s method) are outperforming the 20-year high-quality market corporate bond spot rate of 4.85% as of the time of writing.

4 Non-Cyclical Stocks With High Earnings Yields

FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will participate in fireside chats at the following investor conferences:

Celularity Announces Participation in Upcoming Investor Conferences

Celularity, Inc. (CELU) delivered earnings and revenue surprises of 111.54% and 32.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Celularity, Inc. (CELU) Q2 Earnings Beat Estimates

- Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancers -

Celularity Reports Second Quarter 2022 Financial Results and Corporate Update

CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need

Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

- This research collaboration marks Antengene's entry into the field of cellular medicines. SHANGHAI and HONG KONG July 19, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a pre-clinical research collaboration with Celularity Inc. (NASDAQ: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies.

Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform

FLORHAM PARK, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced it is set to join the broad-market Russell 3000 and the Russell 2000 Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022 according to a preliminary list of additions posted June 3, 2022.

Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®

Halliburton

Mosaic

Nutrien

Occidental Petroleum

These growth stocks have outperformed the broader market by a wide margin this year, delivering outsized gains to shareholders. The post 5 Growth Stocks That a Volatile Market Can't Stop appeared first on InvestorPlace.

5 Growth Stocks That a Volatile Market Can't Stop

Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular Therapies Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular Therapies

Celularity Appoints Industry Leader Diane Parks to its Board of Directors

FLORHAM PARK, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its Class A common stock at a purchase price of $7.40 per share and warrants to purchase 4,054,055 shares of its Class A common stock at an exercise price of $8.25 per share (together the “Securities”) in a private placement priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $30.0 million before deducting placement agent commissions and other estimated offering expenses. The warrants will be exercisable immediately after the date of issuance and will expire five years following the initial issuance date. The closing of the offering and sale of the Securities is expected to occur on or about May 20, 2022, subject to the satisfaction of customary closing conditions.

Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules

FLORHAM PARK, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.

Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

Celularity posted revenue of $21.3M and diluted EPS of -$1.49 for FY-2021. The Company received five FDA fast track/orphan-drug destinations in FY-2021 for its lead candidates.

Celularity: Funds Infusion Needed ASAP To Advance

Two ongoing Phase 1 trials of unmodified placental-derived natural killer cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) and glioblastoma multiforme (GBM)

Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies for cancer, infectious and degenerative diseases, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, and Andrew Pecora, M.D., President of Celularity, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 11:20am ET.

Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference

CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need

Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

Here is how Celularity, Inc. (CELU) and AmerisourceBergen (ABC) have performed compared to their sector so far this year.

Is Celularity, Inc. (CELU) Outperforming Other Medical Stocks This Year?

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

Aptose Biosciences

CNS Pharmaceuticals

Celyad

Spruce Biosciences

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

5 Beaten-Down Biotech Bets to Bounce Back in 2022

FLORHAM PARK, N.J., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

Celularity, Inc. (CELU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why Celularity, Inc. (CELU) is Poised for a Turnaround After Losing 34.3% in 4 Weeks

FLORHAM PARK, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its placental-derived allogeneic genetically modified NK cell therapy program (CYNK-101) and its placental-derived allogeneic CAR-NK cell therapy program (CAR19-CYNK), respectively.  The Company reported its findings in two poster presentations at the 63rd American Society of Hematology Meeting and Exposition (ASH) taking place in Atlanta and virtually December 11-14, 2021.

Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition

News for Celularity Stock (CELU)